Skip to main content
. 2014 Jun 12;6(5):2693–2708. doi: 10.18632/oncotarget.2098

Figure 1. Silvestrol modulates EBV LMP-1 and LMP-1-driven signaling pathways in LCL.

Figure 1

(A) LCL (N=8) were incubated with 0 or 10 nM silvestrol for 72 hr, and whole cell lysates were immunoblotted for LMP-1 and EBNA-2. β-actin was included as a loading control. (B) Lysates from LCL incubated 24, 72, and 120 hr with 0 or 10 nM silvestrol were evaluated by immunoblot. Akata cells (latency I) were treated with 7.5μg/ml anti-IgG for 24 hr to induce lytic cycle. BL41-B95.8 were incubated for 24 hr untreated. Results shown are representative of 3 different LCL. (C) LCL incubated as in (B) were immunoblotted for phosphorylated and total STAT1 and STAT3. Results were representative of 3 LCL. (D) LCL incubated as in (B) were immunoblotted for phosphorylated and total AKT. Results were representative of 3 LCL.